NCT06260748View on ClinicalTrials.gov

A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 27, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Cerebrotendinous Xanthomatoses
Interventions
DRUG

Chenodeoxycholic acid

250mg capsules

DRUG

Chenodeoxycholic acid Placebo

Placebo to match

Trial Locations (1)

Unknown

Sheba Medical Center, Tel Litwinsky

Sponsors
All Listed Sponsors
lead

Leadiant Biosciences, Inc.

INDUSTRY

NCT06260748 - A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX) | Biotech Hunter | Biotech Hunter